Jackson Center, PA, March 9, 2021 – Halberd Corporation’s (OTC PINK:HALB) Chairman, President & CEO, William A. Hartman, was interviewed recently on The Stock Day Podcast, hosted by Everett Jolly. In the interview, Mr. Hartman reviewed the company’s progress in developing SARS-CoV-2 spike protein antibodies and how they can be combined with other Halberd technologies in fighting Covid-19 and other diseases.
Hartman commented on Halberd’s newly created antibody, which has been shown to have a 20 times greater affinity neutralizing than their initial antibody against the SARS-COV-2 antigen. “Our efforts have been focused on developing effective antibodies against not only the spike-protein, but also against the N-protein,” Hartman said. “By publicizing our great progress, we might attract the interests of large company potential partners to assist in accelerating and achieving FDA approval and Emergency Use Authorization. Regardless, we plan to use our superior antibody in our other proprietary technologies, including our radio frequency extracorporeal treatment. Our scientific team agrees that the integration of our radio frequency extracorporeal treatment with the antibody, appears to be a potential break-through technology. If successful in this application, there is no reason why we couldn’t be successful in eliminating all diseases.”
Mr. Hartman outlined the radio-frequency (RF) experimentation being prepared together with GreenBioAz. Initial experimentation will be conducted on eliminating E. Coli bacteria in distilled water, and then moving to more complex media, such as Cerebral Spinal Fluid (CSF) and blood, and also address more contagious diseases. Arrangements are currently underway for the more complex media. Part of the planning deals with instituting the appropriate levels of radiofrequency to eradicate the antigen, adjusting for the effects of the medium itself.
Next, Mr. Hartman provided an update on the creation of Halberd’s vitamin cocktail to boost the body’s immunity and general health. While the name is not yet revealed, we anticipate generating revenue in the second or third quarter.
Mr. Hartman concluded, “We have significant patent opportunities in extracorporeal treatment of disease through radio frequency exposure. Technology will be the driver to our success in the future.”
To listen to the Uptick Everett Jolly podcast, click here.
To get the latest news on Halberd’s exciting developments, subscribe here and submit the form.
For more information please contact:
William A. Hartman
About The “Stock Day” Podcast
Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America. Stock Day recently launched its Video Interview Studio located in Phoenix, Arizona.
About Halberd Corporation.
Halberd Corporation. (OTC-PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Halberd’s Articles of Incorporation prohibit the company from issuance of convertible debt which would result in dilution. See the company’s Articles of Incorporation here.
The company holds the exclusive rights to the COVID-19 extracorporeal treatment technology provisional patent applications: “Method for Treating and Curing Covid-19 Infection;” “Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients;” “Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus,” “Nasal Spray To Prevent The Transmission Of Covid-19 Between Humans,” “Nasal Spray to Prevent the Transmission of Covid-19,” “Method For Treating And Curing Covid-19 Infection By Utilizing Radiofrequency Extracorporeally To Eradicate The Virus,” and “Medication For The Reduction Of Morbidity And Mortality In Persons Infected By Sars-Cov-2 (Covid-19 Virus).” Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.
Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives –
On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.
The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.
The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.
We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.